Alumis Inc.
ALMS
Pozycja w akcjach
#9912
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Cena akcji
$6.78
Kapitalizacja rynkowa
$877.57M
Zmiana (1 dzień)
1.19%
Zmiana (1 rok)
198.68%
Kraj
US
Handel Alumis Inc. (ALMS)
Kategoria
Healthcare
Historia ceny akcji dla Alumis Inc. (ALMS)
Najwyższa cena zamknięcia: $2.34 dnia 2025-05-01
Najniższa cena zamknięcia: $21.58 dnia 2023-05-01
Najniższa cena zamknięcia: $21.58 dnia 2023-05-01
Historia cen akcji firmy Alumis Inc. od 2023 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $136.60 | -4.52% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
